I am not only a GI oncologist who sees patients, but I am also running a laboratory. My research tries to understand why some colon cancers respond to chemotherapy and others don’t, and why some colon cancers recur after successful removal by the surgeon.
I am trying to change the way we treat patients with colon or rectal cancer. Over the last 10 years we have identified genetic signatures which help us choose the most effective and least toxic chemotherapy. In my practice every patient with newly diagnosed colon cancer is genetically tested for KRAS and two genes which show whether FOLFOX chemotherapy is more likely to be successful. Read the rest of this entry »



